# GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)

> **NCT02352974** · PHASE1 · COMPLETED · sponsor: **Johnny Ludvigsson** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** GAD-Alum
- **DRUG:** Vitamin D

## Key facts

- **NCT ID:** NCT02352974
- **Lead sponsor:** Johnny Ludvigsson
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352974, "GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02352974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*